The FDA is reviewing durvalumab with enfortumab vedotin for patients with muscle-invasive bladder cancer who cannot receive ...

A little-known system determines what surgeries are worth. It almost always values men more highly.

A retrospective cohort of 186 patients with seromucinous borderline ovarian tumors found that cystectomy and unilateral ...

American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...

Biodesign brings clinicians, engineers, and other experts together to address real clinical needs, while accounting for regulatory, financial and workflow barriers.

Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial ...

Bladder and Urothelial Cancer Trials to Watch at ESMO 2026 / bladder cancer, cancer, cancer care, Cancer research, cancer ...

A Barcelona study of 87 patients shows that FGFR3 protein overexpression independently predicts recurrence in high-grade T1 ...

The two universities collaborate on addressing disparities in healthcare, accelerating scientific and medical innovation, and ...

A Saudi oncologist says bladder-sparing treatment is possible for some muscle-invasive cancer patients, combining surgery, ...

Which Drugs and Pharma Shaped Oncology in the First Half of 2026? Breaking Down FDA Approvals / BIGR, FDA, OncoDaily, ...

AstraZeneca’s (NYSE: AZN) application to expand Imfinzi into another form of bladder cancer has received FDA Priority Review ...